Protein Microarray System for Rheumatiod Arthritis Diagnosis

用于类风湿性关节炎诊断的蛋白质微阵列系统

• 批准号: 7272614
• 负责人: Ernest Fitch Guignon
• 金额: $ 30万
• 依托单位: CIENCIA, INC.
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-07-15 至 2009-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7272614
• 关键词: Address; Adult; Affect; American; Antibodies; Antigens; Area; Arthritis; Autoimmune Diseases; Autoimmune Process; Bioinformatics; Biological Assay; Biological Markers; Budgets; Cause of Death; Chemistry; Classification; Clinical; Clinical Research; Clinical Trials; Collaborations; Complex; Computer software; Connecticut; Cues; Data; Detection; Development; Device or Instrument Development; Diagnosis; Diagnostic; Diagnostic Procedure; Diagnostic radiologic examination; Diagnostic tests; Disease; Early Diagnosis; Economic Burden; Electronics; Elements; Engineering; Enzyme-Linked Immunosorbent Assay; Female; Foundations; Funding; Future; Generations; Goals; Health; Heart Diseases; Human; Image; Imaging technology; Immobilization; In Vitro; Individual; Joints; Label; Lead; Legal patent; Marketing; Measures; Methods; Molecular; Molecular Target; Monitoring for Recurrence; Monoclonal Antibodies; Morbidity - disease rate; Numbers; Optics; Outcome; Patient Care; Patients; Pattern; Pattern Recognition; Peer Review; Performance; Phase; Phenotype; Physicians' Offices; Physiological; Population; Probability; Process; Protein Microchips; Proteins; Publications; Published Comment; Purpose; Quality of life; Range; Reagent; Recording of previous events; Research; Rheumatoid Arthritis; Sampling; Sensitivity and Specificity; Serum; Societies; Support of Research; Surface; Surface Plasmon Resonance; System; Technology; Testing; Time; United States; United States Food and Drug Administration; Universities; Validation; Work; aqueous; base; biochip; burden of illness; clinical application; cost; cytokine; design; disability; experience; improved; innovation; instrument; interest; late disease onset; method development; multidisciplinary; new technology; outcome forecast; pre-clinical research; programs; prototype; research clinical testing; response; success; technology development; tool

DESCRIPTION (provided by applicant): The diagnosis of rheumatoid arthritis (RA) and other autoimmune disease is a complex challenge that combines the interpretation of a range of physiological cues and molecular assays. Traditionally, radiography has been used to measure RA progression. In vitro diagnostic tests for RA and related diseases consist almost exclusively of single marker tests. There is a well-recognized but unmet need for improved diagnostics based on biological markers to characterize disease type, status, progression, and response to therapy in autoimmune diseases. We are proposing to develop an integrated bioanalytical platform and a clinical research program to facilitate comprehensive differential phenotyping of patient samples on the basis of parallel detection of multiple biomarkers, which when interpreted as a pattern will result in highly predictive and accurate assays. The holistic clinical picture obtained from this advanced protein molecular diagnostic approach will provide the clinician with a powerful tool for early detection, classification, and prognosis, assessment of therapy and monitoring of recurrence, in the treatment of autoimmune disease. This, in turn, should lead to improved patient care, better outcomes and reduced patient care costs. The proposed system will consist of three key elements: an instrument, a protein chip microarray cartridge, and pattern recognition software for analysis. Highly parallel detection of the targeted protein biomarkers is based on an advanced label-free detection technology that we refer to as Grating-Coupled Surface Plasmon Resonance Imaging (GCSPRI). This chip-based technology makes it possible to cost-effectively measure hundreds of analytes simultaneously in near-real time in minute sample volumes (~5 - 50 ¿L). The long-term goal (at the end of Phase II) is to have developed the necessary foundation to be able to proceed expeditiously with FDA approval. The more limited goals of the Phase I (two years) are to develop an integrated prototype bioanalytical diagnostic platform consisting of an instrument and reagent cartridge and to develop and validate a chip designed to assay the presence of relevant analytes in human samples. The platform developed in Phase I would be used in Phase II for human clinical studies. 7. Project Narrative The proposed research aims to develop improved diagnostic methods for rheumatoid arthritis and other autoimmune diseases which affect over 50 million Americans and are a leading cause of death and disability. Anticipated products are expected to improve treatment, reduce morbidity and improve the quality of life of patients suffering from these diseases.

描述（由申请人提供）：类风湿性关节炎（RA）和其他自身免疫性疾病的诊断是一个复杂的挑战，结合了一系列生理线索和分子分析的解释。传统上，x线摄影已被用于测量RA的进展。类风湿性关节炎及相关疾病的体外诊断测试几乎完全由单一标记物测试组成。在自身免疫性疾病中，有一个公认但尚未满足的需求，即改进基于生物标志物的诊断，以表征疾病类型、状态、进展和对治疗的反应。我们建议开发一个集成的生物分析平台和临床研究项目，以促进在多种生物标志物平行检测的基础上对患者样本进行全面的差异表型分析，当这些生物标志物被解释为一种模式时，将导致高度预测和准确的分析。从这种先进的蛋白质分子诊断方法中获得的整体临床图像将为临床医生提供一种强大的工具，用于自身免疫性疾病的早期发现、分类、预后、治疗评估和复发监测。反过来，这应该会改善患者护理，改善结果并降低患者护理成本。提出的系统将包括三个关键要素：一个仪器，一个蛋白质芯片微阵列盒，以及用于分析的模式识别软件。靶向蛋白生物标志物的高度平行检测是基于一种先进的无标记检测技术，我们称之为光栅耦合表面等离子体共振成像（GCSPRI）。这种基于芯片的技术可以经济有效地同时以近乎实时的方式测量数百种分析物，样品体积为分钟（~5 - 50¿L）。长期目标（在第二阶段结束时）是建立必要的基础，以便能够迅速获得FDA的批准。第一阶段（两年）更有限的目标是开发一个集成的原型生物分析诊断平台，由仪器和试剂盒组成，并开发和验证设计用于分析人类样本中相关分析物存在的芯片。I期开发的平台将用于II期人体临床研究。7. 拟议的研究旨在开发改进的类风湿性关节炎和其他自身免疫性疾病的诊断方法，这些疾病影响着5000多万美国人，是导致死亡和残疾的主要原因。预期的产品有望改善这些疾病患者的治疗、降低发病率和改善生活质量。